Johnson & Johnson vs TransMedics Group, Inc. — Stock Comparison
Q·Score Breakdown
7.1
Bullish
Overall
8.8
Very Bullish
Quality
Health
Growth
Valuation
Sentiment
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
TMDX
Earnings growing 1188% year-over-year on 32% revenue growth.
Analyst Consensus
BUY
Target $252.42 (+11.1%)
24 analysts
BUY
Target $156.00 (+56.0%)
10 analysts
Fundamentals
JNJ
TMDX
26.3×
Trailing P/E
20.5×
17.9×
Forward P/E
27.2×
21.8%
Profit Margin
31.4%
68.0%
Gross Margin
59.9%
26.4%
ROE
54.2%
9.9%
Revenue Growth
32.2%
-52.9%
Earnings Growth
1188.1%
0.33
Beta
2.08
—
Price / Book
—
$546.9B
Market Cap
$3.5B
$146 – $252
52-Week Range
$90 – $156
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →